Warren Buffett bought 4 pharma giants in Q3

The Oracle of Omaha and his team opened new positions in the underperforming sector.

Legendary share market investing expert, and owner of Berkshire Hathaway, Warren Buffett.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) filed its Form 13F with the Securities and Exchange Commission on Monday, which gave investors a look at what the Oracle of Omaha and his team of investors bought in the third quarter.

Among the list were four pharmaceutical companies: AbbVie (NYSE: ABBV), Merck (NYSE: MRK), Bristol Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE). The first three were similarly sized purchases of around $1.8 billion. The Pfizer purchase was substantially smaller, with a market value around $136 million.

Within the industry, there doesn't seem to be a theme among the four drugmakers.

Merck and Bristol Myers are heavily into oncology. Bristol Myers expanded its cancer treatments last year with the acquisition of Celgene. Merck is hanging its hat on Keytruda with plans to spin out its women's health and cardiovascular drugs, as well as some other brands into Organon & Co. next year.

AbbVie is looking to diversify away from its reliance on its megablockbuster Humira, which treats a variety of inflammatory disorders. The pharmaceutical company made a big move into dermatology with the acquisition of Allergan, the maker of Botox, which closed earlier this year.

Pfizer is currently most famous for its coronavirus vaccine, but the pharma giant is quite diversified. Like Merck, Pfizer is looking to get more focused by merging its Upjohn generic-drug business with Mylan in a new company called Viatris that's scheduled to start trading on Tuesday. Investors will have to wait for the next Form 13F to see what Buffett does with the shares of Viatris that all Pfizer shareholders received.

The pharmaceutical companies do have one thing in common: They're all trading off their all-time highs and have been for all of 2020, suggesting Buffet might be bargain shopping.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Brian Orelli, PhD has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Berkshire Hathaway (B shares) and recommends the following options: long January 2021 $200 calls on Berkshire Hathaway (B shares), short January 2021 $200 puts on Berkshire Hathaway (B shares), and short December 2020 $210 calls on Berkshire Hathaway (B shares). The Motley Fool Australia has recommended Berkshire Hathaway (B shares). We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on International Stock News

woman happy while charging her Tesla
International Stock News

Is Cathie Wood actually right about Tesla stock?

Here's the lowdown.

Read more »

A family sits on their couch, eyes glued to the television.
International Stock News

Could Netflix Stock Help You Become a Millionaire?

Netflix is now worth $520 billion, making it one of the world's most valuable businesses.

Read more »

Happy woman working on a laptop.
International Stock News

This AI stock has climbed 26,510%, and it's still a buy

Let's find out more.

Read more »

A man with a wide, eager smile on his face holds up three fingers.
International Stock News

Which 3 tech giants could cross the $3 trillion mark next?

Let's take a closer look at these three stocks and see what it will take for them to get there.

Read more »

Humanoid robot analysing the stock market, symbolising artificial intelligence shares.
International Stock News

Cathie Wood says if she could only invest in 1 artificial intelligence (AI) stock, this would be it (Hint: It's Not Palantir)

Let's dig into why this stock has earned so much confidence from Wood.

Read more »

Woman in business suit holds both hands out with a question mark above each hand.
International Stock News

Better core AI stock: Nvidia or Palantir Technologies?

Which of these top innovation stocks is the better buy as a core AI holding?

Read more »

A Tesla car driving along a road at sunset.
International Stock News

Prediction: This artificial intelligence (AI) stock could be the biggest winner of the second half of 2025

Let's take a look.

Read more »

Digital rocket on a laptop.
International Stock News

Prediction: After losing more than $1 trillion in market cap earlier this year, this monster artificial intelligence (AI) stock will become the most valuable business in the world by the end of the year

I'll explain why investor enthusiasm is on the rise and detail why I think the stock is poised for an…

Read more »